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Purpose. The aim of this study was to assess the impact of immunohistochemical- (IHC-) studies on incidence and survival of lung
cancer histotypes. Patients and Methods. Lung cancers occurred in southern Switzerland between 1996 and 2010 were selected by
the Ticino Cancer Registry and categorised into adenocarcinoma (AC), squamous-cell-carcinoma (SqCC), small-cell-carcinoma
(SmCC), and large-cell carcinoma/non-small-cell lung cancer (LCC/NSCLC). Incidence rates, annual-percentage-change (APC),
and two-year overall survival (OS) (follow-up: 31.12.2010) were performed. Results. 2467 cases were selected: 997 (40.4%) AC; 522
(21.2%) LCC/NSCLC, 378 (15.3%) SmCC, and 570 (23.1%) SqCC. Trend-analysis showed signiﬁcant increase in AC (APC: 4.6;
95% CI: 3.1; 6.0) and decrease of LCC/NSCLC, with signiﬁcant joinpoint in 2003 (APC: −14.7; 95% CI: −21.6; −7.1). Improved
OS and decreased OS were detected in SqCC and LCC/NSCLC, respectively. Conclusions. This study highlights that diagnosis
with ancillary immunohistochemical studies will change incidence and survival of precisely deﬁned lung cancer subtypes. It
calls attention to the need for cautious interpretation of studies and clinical trials, where the diagnosis was based on histology
unaccompanied by IHC studies, and to the need of standardised diagnostic procedures.
1.Introduction
Lung cancer is one of most common cancers in the world,
representing 17.1% of all cancers in men, 6.7% in women,
and 12.2% in both sexes [1]. Of the histological types, ade-
nocarcinoma (AC) has remained the most prevalent among
women over the past three decades, with incidence rates
increasing slowly over time in many countries. In contrast,
squamous cell carcinoma (SqCC) has historically been the
predominant tumour type in men, but the incidence has
declined and converged with the corresponding incidence in
women, which has remained fairly stable [2].
Traditionally,lungcarcinomawasclassiﬁedintohistolog-
ical types using standard histological techniques. The most
critical step in histopathological diagnosis was to distin-
guish small cell carcinoma (SmCC) from the other lung
carcinomas, which were collectively called the non-small cell
lung carcinomas (NSCLCs); patients with the former were
referred to chemotherapy, whereas patients with the latter
were potentially eligible for surgery or diﬀerent chemother-
apies. Over the past few years, the emergence of targeted or
combination treatment strategies has created new demands
on histopathological diagnostics, as it is now recognised that
the eﬃcacy and toxicity of some new drugs are related to the
histological type [3]. Consequently, the exact determination
of histological type by a pathologist has become essential to
making clinical decisions [4].
Inthiscontext,theintegrationofconventionalhistomor-
phological analysis with an immunohistochemical (IHC)
panel that includes markers of squamous (i.e., p63, cytok-
eratin (CK) 5/6) and glandular (TTF-1, CK7) cell diﬀeren-
tiation allows more accurate identiﬁcation of the histotype
[5–12]. Moreover, recent studies have demonstrated that the
antibody panel approach may help to reﬁne lung cancer2 Journal of Cancer Epidemiology
classiﬁcation in ﬁne needle aspiration (FNA) cell blocks as
well as in biopsy material; remarkably, this approach reduces
the proportion of cancers diagnosed as NSCLCs and thus
improves the quality of treatment decisions [11, 13].
The aims of this study were as follows: (i) to assess
changes in lung cancer incidence in the south of Switzerland
after the progressive introduction from 2003 to 2009 of
ancillary IHC studies for the diagnosis of lung cancers (panel
systematically applied from 2010) and (ii) to evaluate poten-
tial changes in short-term survival trends of the four major
lung cancer histotypes.
2.MaterialandMethods
2.1. Case Selection. All patients with invasive lung cancer
diagnosed by cytology or histology in the south of Switzer-
land between 1996 and 2010 were selected from the ﬁles of
the population-based Ticino Cancer Registry. The Registry is
located in the southern, Italian-speaking region of Switzer-
land and is closely connected to and part of the region-
al Institute of Pathology, which serves the entire region [14].
Lung tumour topography and lung tumour histotypes
were classiﬁed using the International Classiﬁcation of Dis-
eases for Oncology (ICD-O-III) and the WHO Classiﬁcation
of Tumours of the Lung [15, 16] .T h et u m o u rs i t ew a sc l a s -
siﬁed according to the extended ICD-O version proposed by
Wagner [17]. Case registration and comparability, validity,
and consistency checks were performed according to the
International Agency for Research on Cancer (IARC) guide-
lines and the recommendations of the European Network of
Cancer Registries (ENCRs) [18–20].
Lung cancers were categorised into four histotypes:
AC, SqCC, SmCC, and large cell carcinoma/non-small-cell
lung cancer (LCC/NSCLC) [15, 16]. We included NSCLC,
not formally classiﬁed by WHO, in the LCC histotype,
as considered by default “poorly diﬀerentiated” tumours,
resulting in the group called LCC/NSCLC [16]. Carcinomas
not otherwise speciﬁed (NOS), lymphomas, neuroendocrine
tumours (i.e., carcinoids and large cell neuroendocrine
carcinomas),andmesenchymaltumourswereexcludedfrom
the present study. Tumours were staged according to the
Cancer Staging Manual of the American Joint Committee
on Cancer (AJCC), version 5, until 2002 and according
to version 6 from 2003 onwards. The tumours were then
categorised as “limited disease” (any T, any N, and M0) or
“extensive disease” (any T, any N, and M1) [16, 21, 22].
All histological evaluations were made at the local
Instituteofpathologybythesamecoregroupofpathologists.
IHC studies for histotyping lung cancers (i.e., TTF-1, p63,
CK 5/6 and 7) were progressively introduced from 2003 to
2009. Since 2010 a diagnostic algorithm is applied to all new
cases systematically.
2.2. Statistical Analysis. Mean and median values are pro-
vided for quantitative variables; proportions represent qual-
itative variables. Diﬀerences among lung cancer histotypes
were evaluated using 1-way analysis of variance (ANOVA)
for patient age (years). A chi-square test was conducted to
assess the relationship between the diﬀerent lung cancer
histotypes and main clinicopathological characteristics such
as sex, histological grade, and tumour extent at diagnosis.
TheKruskalWallistestwasusedtocompareordinalvariables
such as age groups.
European age-standardised incidence rates were cal-
culated by the direct standardization method to remove
the strong correlation between patient age and tumour
occurrence [23]. Trends in incidence were measured as the
estimated annual percentage change (APC) and the 95%
conﬁdence interval (CI), which were calculated by ﬁtting a
linear regression to the natural logarithm of the age-adjusted
rates (r), with year of diagnosis as the regressor variable
as follows: ln(r) = m(year) + b.F r o mm, the slope of
theregressionline,theAPCwascalculatedasfollows:APC =
100 × (em − 1) [24–26]. Incidence trends were analysed by
lung cancer histotypes for both genders together. Statistical
signiﬁcance was set at P<0.05. Two-year overall survival
(OS) (follow-up on December 31, 2010) was analysed for
patients with a 24-month complete follow-up (incidence
period 1996–2008) using the Kaplan-Meier method. The
logrank test was used to detect statistically signiﬁcant
diﬀerences in survival. The two-year survival trend analysis
considered three incidence periods: 1996–2001 (before the
introduction of the IHC panel), 2002–2004 (transitional
period), and 2005–2008 (after the introduction of the
complete IHC panel). The statistical analysis was conducted
in SAS version 9.1 (SAS Institute Inc, Cary, NC, USA).
3. Results
Of 2844 lung cancers that occurred in the south of Switzer-
land between 1996 and 2010, 2585 (90.9%) were conﬁrmed
by cytological or histological assay and were therefore
selected for inclusion in the present study. The 118 cases that
did not meet the inclusion criteria (i.e., carcinomas NOS,
lymphomas, neuroendocrine, and mesenchymal tumours)
were excluded from the analysis, and the remaining 2467
cases constitute the basis of the present study. The prevalence
of each of the four lung cancer histotypes was as follows:
997 (40.4%) ACs, 522 (21.2%) LCC/NSCLCs, 378 (15.3%)
SmCCs, and 570 (23.1%) SqCCs.
Table 1 summarises the main clinical-pathological char-
acteristics of the patients. The four lung cancer histotypes
diﬀered signiﬁcantly by mean age at diagnosis (ANOVA
F-test = 7.49, P<0.0001), AC being dominant in the
youngest group (66.0 ± 11.0 years old). When subjects were
stratiﬁed by age group, this result was conﬁrmed (P<
0.0001). Overall, most lung cancers occurred in men (69%),
with a pick of 80.5% in SqCC (P<0.0001). In terms of
histological grade at diagnosis, 62.6% of AC tumours and
54.2% of SqCC tumours were poorly diﬀerentiated (P =
0.0048). A signiﬁcant diﬀerence was found when lung cancer
histotypes were compared by tumour extent at diagnosis
(P<0.0001): SqCC showed the highest prevalence of limited
disease (77.2%), whereas >50% of SmCCs were classiﬁed as
“extensive”. We also detected an overall signiﬁcant diﬀerence
(P<0.0001) in the distribution of histotypes across the twoJournal of Cancer Epidemiology 3
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Figure 1: Trend of European age-standardised incidence rates of lung cancer histotypes: Ticino, 1996–2010.
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Figure 2: Trend in European age-standardised incidence rates of poorly diﬀerentiated lung cancer histotypes: Ticino, 1996–2010.
study periods (Table 1). In particular, we observed a higher
proportion of AC tumours after 2003 (40.9% in 1996–2003
versus 59.1% in 2004–2010, P<0.0001), corresponding to
a percentage increase of 44.5% of the total cases; in contrast,
there was a signiﬁcant decrease in LCC/NSCLC proportion
(64.0% in 1996–2003 versus 36.0% in 2004–2010, P<
0.0001), corresponding to a percentage decrease of 43.8%.
The prevalence of SmCC and SqCC remained stable.
The above-described trends of proportions were con-
ﬁrmed by the trend analysis of incidence rates, which show
a signiﬁcant increase in AC incidence (Figure 1,A P C :4 . 6 ;
95% CI: 3.1; 6.0) accompanied by a decrease in LCC/NSCLCJournal of Cancer Epidemiology 5
incidence, with a signiﬁcant joinpoint in 2003 (APC: −14.7;
95% CI: −21.6; −7.1). We also detected a slight decrease in
the incidence of SqCC and SmCC, but it was not statistically
signiﬁcant. The trend seen in AC was also observed when we
consideredonlypoorlydiﬀerentiatedlungcancers(APC:5.1;
9 5 %C I :3 . 4 ;6 . 8 )( Figure 2).
Short-term OSs by lung cancer histotype are reported in
Figure 3; SmCCs and LCC/NSCLCs show the worst survival
probabilities at two years from diagnosis (P<0.0001). We
also detected an increase in OS for SqCC and a decrease for
LCC/NSCLC,particularlyinthelaststudyperiod,2005–2008
(Figure 4).
4. Discussion
The observed baseline increase in the incidence of AC and
decrease in the incidence of SqCC, which were observed in
both genders, are similar to the trends observed worldwide
and described in many studies [27–29]. The decreased inci-
denceofsmokinginmen,theincreasedincidenceofsmoking
in women, accompanied by changes in the composition of
cigarettes, and the implementation of ﬁlters are suggested to
be responsible for the observed changes [2, 30]. It has also
been postulated that the use of ﬁltered cigarettes has caused
an increase in the incidence of AC, which is usually located
in the peripheral lung, because smokers now need to inhale
more deeply to achieve a comparable eﬀe c t .T h ee x p o s u r eo f
the lung tissue to tobacco smoke is thus more extensive [31].
In addition to the increasing incidence of AC, our
study highlights a signiﬁcant decrease in the incidence of
the LCC/NSCLC histotype, with a joinpoint in 2003. This
observation is diﬃcult to explain by changes in exposure to
known lung cancer risk factors. More likely it is associated
with the progressive introduction (beginning in 2003) of a
panel of IHC markers for squamous (i.e., p63, CK 5/6) and
glandular diﬀerentiation (TTF-1, CK7). Many studies have
already described the beneﬁt to diagnosis of a speciﬁc panel
of markers that can help pathologists to correctly classify
lung cancer histotypes [32–34]. In particular, major beneﬁts
are obtained in distinguishing poorly diﬀerentiated SqCC
from AC, especially in small biopsy tissues or cell specimens
obtained by bronchus brossage/lavage or FNA [6–9, 35]. In
recent years, a precise histopathological classiﬁcation of lung
carcinomas has become increasingly important as a way to
identify candidates for targeted therapy and to improve the
design of clinical trials [3, 12]. Thus, the observed decrease
in LCC/NSCLC diagnosis and increase in AC diagnosis will
help to better deﬁne the target populations that could beneﬁt
from these new drugs.
Concerning potential confounding factors, it is unlikely
that WHO’s 2003 changes in lung cancer classiﬁcation
(1996–2002, according to the second edition of the Inter-
national Classiﬁcation of Diseases for Oncology (ICD-O-
II); 2003–2010, according to the third edition (ICD-O-III))
signiﬁcantly inﬂuenced our results. Before the introduction
of ICD-O-III in 2003, LCC and NSCLC were routinely con-
sideredtogetherasapoorlydeﬁnedandpoorlydiﬀerentiated
entity (since 2003 the NSCLC code was not available in ICD-
O codes, and as consequence LCC diagnosis was treated as a
1
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Figure 3: Short-term overall survival by lung cancer histotypes:
Ticino, 1996–2008.
“catch-all”). In order to avoid classiﬁcation bias, we pooled
these two groups in the second study period as well. Another
potential confounding factor (not observed in our study,
data not shown) would be a shift along the study period in
diagnostic procedure (i.e., cytology versus histology), which
could cause an increase or decrease in diagnostic accuracy.
The signiﬁcant changes in incidence by histological
subtype appear to be followed by changes in the short-term
OS. This trend, which is most evident for LCC/NSCLC and
SqCC, is important, as it could have aﬀected the results of
some clinical trials, particularly in cases where the diagnosis
of lung cancers was based on histological evaluation without
ancillary studies, or where ancillary studies were progres-
sively introduced over the study period. In this contest, the
worstshort-termOSforLCC/NSCLCinthelastperiodofthe
study (Figure 4) most likely reﬂects the selection of poorly
diﬀerentiated carcinomas. Additional studies are warranted
to clarify this observation as well as the improved short-term
OS of patients with SqCC that may be related to a general
improvement of cancer care.
The most signiﬁcant aspects of this study are the fol-
lowing: (i) it includes an up-to-date case study (1996–2010)
composed of a large number of lung cancer cases, thus
reﬂecting a representative real-world description of a popu-
lation with universal and homogeneous access to treatment;
(ii) all ages were considered, thereby ensuring the observa-
tion of a total population at risk; (iii) the panel analyses of
diagnostic markers were all carried out by a single laboratory
and evaluated on routinely collected tissue by the same core6 Journal of Cancer Epidemiology
AC: adenocarcinoma; LLC/NSCLC: large-cell carcinoma/non-
small-cell lung cancer
SmCC: small-cell carcinoma; SqCC: squamous cell carcinoma
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Figure 4: Trend in two-year overall survival by lung cancer
histotypes: Ticino, incident cases in the periods 1996–2001, 2002–
2004, and 2005–2008.
group of pathologists, thus ensuring the reproducibility of
results.
In conclusion, in this population-based study we
observed a statistically signiﬁcant decrease of LCC/NSCLC
histotype, which is most likely attributable to the introduc-
tion of IHC diagnostic markers. We underscore the need
for cautions interpretation of previous studies and clinical
trials in which the diagnosis of lung cancer was only based
on conventional histomorphological evaluation. In the era
of targeted therapy, we advocate not only quality control
programs for molecular testing but also a standardisation of
histological diagnoses.
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